Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,longTermDebt,otherCurrentLiab,changeToLiabilities,investments,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,priceHint,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,exchangeDataDelayedBy,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,marketState,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,country,website,maxAge,address1,industry,address2
t0,GRCL,2194436000.0,67213200,65433000,,-97665000,,-97665000,31759000,0,-97192000,-97192000,,-1235000,,,,0,0,97192000,0,-473000,,-97665000,-99654000,2858181000.0,193621000.0,2194436000.0,2388057000.0,222000.0,54899000.0,-663683000.0,11078000.0,-284000.0,19902000.0,2157833000.0,121020000.0,874000.0,-284000.0,143809000.0,2224346000.0,11614000.0,51926000.0,,0.0,,,,,,,,,,,,,2103326000.0,en-US,US,EQUITY,True,Delayed Quote,10.17,1630526402,-0.26000023,10.47,10.71,10.12,30428,-4.687826,-0.31551224,683558272,15,America/New_York,EDT,-14400000,False,False,USD,2,Gracell Biotechnologies Inc.,NMS,-0.61,-16.67213,11.205428,-1.035428,-0.09240415,14.857826,0,finmb_604186415,NasdaqGS,Gracell Biotechnologies Inc.,CNY,116551,67557,0.42000008,0.043076932,9.75 - 33.7,-23.53,-0.6982196,9.75,33.7,1621254600,1621254600,1621254600,PREPRE,-2.4928114,10.12 - 10.71,10.43,0.0,0.0,14,9,us_market,,,,33.7,9.75,11.21,14.86,116.55k,67.56k,67.21M,,35.52M,0.00%,32.63%,699.97k,5,,1.04%,392.49k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-252.9M,-331.59M,,,2.17B,35.62,138.63M,6.32,18.38,,,,Value,215123,Healthcare,202,"Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.",Suzhou,86 512 6262 6701,China,http://www.gracellbio.com,86400,"Building 12, Block B",Biotechnology,"Phase II, Biobay Industrial Park 218 Sangtian Street Suzhou Industrial Park"
t-1,GRCL,-587873000.0,67213200,60693000,,-83593000,,-83593000,24785000,0,-85478000,-85478000,,-805000,,,,0,0,85478000,0,1885000,,-83593000,-99934000,,145287000.0,-587873000.0,964950000.0,68000.0,35797000.0,-564029000.0,,-23912000.0,30398000.0,754308000.0,93361000.0,970000.0,-23912000.0,119083000.0,815469000.0,22069000.0,51926000.0,2623000.0,0.0,1959000.0,-12151000.0,38006000.0,693128000.0,9612000.0,597527000.0,-19496000.0,-63954000.0,9350000.0,-3144000.0,677000.0,-14110000.0,722108000.0,en-US,US,EQUITY,True,Delayed Quote,10.17,1630526402,-0.26000023,10.47,10.71,10.12,30428,-4.687826,-0.31551224,683558272,15,America/New_York,EDT,-14400000,False,False,USD,2,Gracell Biotechnologies Inc.,NMS,-0.61,-16.67213,11.205428,-1.035428,-0.09240415,14.857826,0,finmb_604186415,NasdaqGS,Gracell Biotechnologies Inc.,CNY,116551,67557,0.42000008,0.043076932,9.75 - 33.7,-23.53,-0.6982196,9.75,33.7,1621254600,1621254600,1621254600,PREPRE,-2.4928114,10.12 - 10.71,10.43,0.0,0.0,14,9,us_market,,,,33.7,9.75,11.21,14.86,116.55k,67.56k,67.21M,,35.52M,0.00%,32.63%,699.97k,5,,1.04%,392.49k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-252.9M,-331.59M,,,2.17B,35.62,138.63M,6.32,18.38,,,,Value,215123,Healthcare,202,"Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.",Suzhou,86 512 6262 6701,China,http://www.gracellbio.com,86400,"Building 12, Block B",Biotechnology,"Phase II, Biobay Industrial Park 218 Sangtian Street Suzhou Industrial Park"
t-2,GRCL,-292487000.0,67213200,27355000,,-31954000,,-31954000,5625000,0,-32980000,-32980000,,-206000,,,,0,0,32980000,0,1026000,,-31954000,-42693000,,,-292487000.0,,,,,,,,,,,,,,,,,0.0,1959000.0,-12151000.0,38006000.0,693128000.0,9612000.0,597527000.0,-19496000.0,-63954000.0,9350000.0,-3144000.0,677000.0,-14110000.0,,en-US,US,EQUITY,True,Delayed Quote,10.17,1630526402,-0.26000023,10.47,10.71,10.12,30428,-4.687826,-0.31551224,683558272,15,America/New_York,EDT,-14400000,False,False,USD,2,Gracell Biotechnologies Inc.,NMS,-0.61,-16.67213,11.205428,-1.035428,-0.09240415,14.857826,0,finmb_604186415,NasdaqGS,Gracell Biotechnologies Inc.,CNY,116551,67557,0.42000008,0.043076932,9.75 - 33.7,-23.53,-0.6982196,9.75,33.7,1621254600,1621254600,1621254600,PREPRE,-2.4928114,10.12 - 10.71,10.43,0.0,0.0,14,9,us_market,,,,33.7,9.75,11.21,14.86,116.55k,67.56k,67.21M,,35.52M,0.00%,32.63%,699.97k,5,,1.04%,392.49k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-252.9M,-331.59M,,,2.17B,35.62,138.63M,6.32,18.38,,,,Value,215123,Healthcare,202,"Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.",Suzhou,86 512 6262 6701,China,http://www.gracellbio.com,86400,"Building 12, Block B",Biotechnology,"Phase II, Biobay Industrial Park 218 Sangtian Street Suzhou Industrial Park"
t-3,GRCL,-292487000.0,67213200,37967000,,-42805000,,-42805000,7925000,0,-45892000,-45892000,,-206000,,,,0,0,45892000,0,3087000,,-42805000,-53431000,,156861000.0,-292487000.0,412217000.0,68000.0,14709000.0,-289396000.0,,-3159000.0,23541000.0,312058000.0,18166000.0,,-3159000.0,48323000.0,340353000.0,8159000.0,138695000.0,340000.0,0.0,8881000.0,-1360000.0,38006000.0,693128000.0,9127000.0,-37916000.0,-3773000.0,-32783000.0,1324000.0,-3144000.0,-429000.0,-10241000.0,322187000.0,en-US,US,EQUITY,True,Delayed Quote,10.17,1630526402,-0.26000023,10.47,10.71,10.12,30428,-4.687826,-0.31551224,683558272,15,America/New_York,EDT,-14400000,False,False,USD,2,Gracell Biotechnologies Inc.,NMS,-0.61,-16.67213,11.205428,-1.035428,-0.09240415,14.857826,0,finmb_604186415,NasdaqGS,Gracell Biotechnologies Inc.,CNY,116551,67557,0.42000008,0.043076932,9.75 - 33.7,-23.53,-0.6982196,9.75,33.7,1621254600,1621254600,1621254600,PREPRE,-2.4928114,10.12 - 10.71,10.43,0.0,0.0,14,9,us_market,,,,33.7,9.75,11.21,14.86,116.55k,67.56k,67.21M,,35.52M,0.00%,32.63%,699.97k,5,,1.04%,392.49k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,,,,,,,-252.9M,-331.59M,,,2.17B,35.62,138.63M,6.32,18.38,,,,Value,215123,Healthcare,202,"Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.",Suzhou,86 512 6262 6701,China,http://www.gracellbio.com,86400,"Building 12, Block B",Biotechnology,"Phase II, Biobay Industrial Park 218 Sangtian Street Suzhou Industrial Park"
